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Abstract: Background: The aim was to compare two different systemic antibiotics regimens
adjunctive to non-surgical periodontal therapy when Aggregatibacter actinomycetemcomitans was
not detected in the subgingival biofilm. Methods: A total of 58 patients with periodontitis and with
no A. actinomycetemcomitans in the subgingival biofilm were treated with full-mouth subgingival
instrumentation and either metronidazole (MET; n = 29) or amoxicillin/metronidazole (AMX/MET;
n = 29). Probing depth (PD), clinical attachment level (CAL) and bleeding on probing (BOP) were
recorded at baseline, as well as after three and six months. Subgingival biofilm and gingival crevicular
fluid were collected and analyzed for major periodontopathogens and biomarkers. Results: PD,
CAL and BOP improved at 3 and 6 months (each p < 0.001 vs. baseline) with no difference between
the groups. Sites with initial PD ≥ 6 mm also improved in both groups after 3 and 6 months (p < 0.001)
with a higher reduction of PD in the AMX/MET group (p < 0.05). T. forsythia was lower in the
AMX/MET group after 3 months (p < 0.05). MMP-8 and IL-1β were without significant changes and
differences between the groups. Conclusion: When A. actinomycetemcomitans was not detected in the
subgingival biofilm, the adjunctive systemic use of amoxicillin/metronidazole results in better clinical
and microbiological outcomes of non-surgical periodontal therapy when the application of systemic
antibiotics is scheduled.
Keywords: scaling and root planing; antibiotics; periodontitis; non-surgical treatment
1. Introduction
Periodontitis is a chronic inflammatory, autodestructive disease [1,2] with high prevalence [3–5].
The tooth-supporting tissues are progressively destructed and subsequent tooth loss can occur.
Subgingival instrumentation is an efficacious part of the systematic periodontal treatment [6–10].
Systemic antimicrobials as an adjunct to subgingival instrumentation statistically significantly improve
the clinical results of the nonsurgical therapy. There exist proves of positive effects of several antibiotics
regarding the reduction of probing depth (PD) and bleeding on probing (BOP) and additional
attachment gain (CAL) is also reported [11]. The adjunctive use of antibiotics is not without any
concern respecting public and patient´s health. Following this, it is not recommended to treat all
periodontitis patients routinely with adjunctive antibiotics (Treatment of stage I-III Periodontitis) [12].
However, higher initial probing depths benefit from systemic antibiotics adjunctively given to the
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subgingival instrumentation [13]. Moreover, the number of sites to be treated surgically is diminished
by adjunctive antibiotics to subgingival instrumentation [11].
Severalbacterialspecies, suchasAggregatibacteractinomycetemcomitans [14,15],Porphyromonasgingivalis [15,16],
Treponema denticola, and Tannerella forsythia [17,18], trigger the local inflammation and are proven to damage and
destroy periodontal tissues.
The capnophilic A. actinomycetemcomitans is most sensitive to amoxicillin but resistant to
metronidazole, while the other Gram-negative but strictly anaerobe bacteria (e.g., P. gingivalis) are most
highly sensitive to metronidazole [19–21]. Contrastingly, there is not always a high susceptibility of
bacteria in the subgingival biofilm to amoxicillin [22]. This raised the question as to whether, in the
absence of A. actinomycetemcomitans, the administration of amoxicillin could be avoided.
The combination of amoxicillin and metronidazole is widely used in the periodontal therapy [23].
Empiric adjunctive use of antibiotics without testing the composition of the subgingival biofilm results
mostly in the prescription of the combination of amoxicillin and metronidazole [24]. On the other
hand, studies and reviews describing the positive results of the adjunctive medication with amoxicillin
and metronidazole did not differentiate between A. actinomycetemcomitans-positive or -negative tested
biofilms or patients.
To the best of the authors’ knowledge, no study has been performed to compare the clinical
results and the effects on several periodontopathogens and biomarkers after administration of
amoxicillin and metronidazole or metronidazole alone in A. actinomycetemcomitans-negative patients
adjunctively prescribed to subgingival instrumentation. The aim of the study is to verify if there exist
differences between the prescription of solely metronidazole versus the combined antibiotic therapy
with amoxicillin and metronidazole in patients where an adjunctive antibiotic regime is scheduled.
The hypothesis of the present study was that the prescription of amoxicillin/metronidazole results in
better outcomes at the clinical variables PD, CAL and BOP than the use of solely metronidazole as an
adjunct to subgingival instrumentation in patients tested negative for A. actinomycetemcomitans in the
subgingival biofilm.
2. Materials and Methods
2.1. Patients
The study protocol was approved by the Ethics Committee at the Medical Faculty, Leipzig University
(078-16-14032016) and followed the principles of the Declaration of Helsinki, as revised in 2013. It is
deposited at the German register of clinical trials (DRKS00015193). The study participants were
recruited and treated in a private dental practice with experiences in the field of periodontology (M.D.).
The treatment was supervised by a specialist for periodontology (H.J.). Every volunteer was fully
informed and gave written consent to participate in the study.
Criteria for being included in the study were having no less than 16 teeth (minimum four in each
quadrant) and at least two independent sites with probing depths ≥ 6 mm per quadrant and a full
mouth plaque score below 35% after two sessions of professional prophylaxis and instruction similar
to the inclusion criteria of Haffajee et al. (2007). Exclusion criteria were antibiotic treatment within
the last three months, periodontal therapy within the last year, pregnancy or breastfeeding period
and conditions or systemic diseases affecting the periodontal tissues. A further exclusion criterion
was the detection of A. actinomycetemcomitans in the subgingival biofilm tested by analysis of the
subgingival biofilm two weeks before subgingival instrumentation. From the recruited 82 patients,
four refused to participate and 23 had to be excluded due to the presence of A. actinomycetemcomitans
in the subgingival biofilm or other reasons for exclusion. Following this, 58 participants remained in
the study. The allocation to the two study groups was made with a computer-generated table in a ratio
1:1. All examinations and the treatment were performed by one clinician (M.D) who was unaware
about the study group. The delivery of the assigned antibiotics was made by a dental assistant of
the dental practice (M.W.) who was not involved in the treatment of the patient. Unblinding of the
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data was made after recording all patients’ data. The prior intra-examiner calibration performed by
repeated measurements of PD in two quadrants of eight patients resulted in κ = 0.88.
2.2. Therapy and Follow-Up Treatment
Both groups received the same full-mouth subgingival instrumentation in one session within
four weeks after baseline examination (after receiving the results of the microbiological testing of the
subgingival biofilm for A. actinomycetemcomitans). Subgingival instrumentation was conducted by using
articaine hydrochloride/epinephrine hypochloride for local anesthesia (Ultracain D-S, Sanofi-Aventis,
Frankfurt/Main, Germany) and hand (Gracey Curettes Mini Five rigid, Hu-Friedy Manufacturing
Co., Chicago, IL, USA) and ultrasonic instruments (EMS SA, Nyon, Switzerland) for the subgingival
instrumentation. The test (metronidazole (MET)) group received 3 × 400 mg metronidazole from the
first day of subgingival instrumentation, and the control (amoxicillin (AMX)/MET) group received a
combination of 3 × 400 mg metronidazole and 3 × 500 mg amoxicillin both for one week. The drug
packages were not blinded. In the first week after treatment, each individual performed normal
careful oral hygiene with tooth and interdental brushes supplemented by one minute rinsing with
a chlorhexidine digluconate mouthrinse (Chlorhexamed forte 0.2%, GlaxoSmithKline Healthcare,
Bühl, Germany) twice a day. Exact drug use was reinforced by telephone calls. For the case of any
adverse effect the patients were instructed to address the dental practice. After three and six months,
the participants received supportive periodontal treatment including re-motivation and reinstruction.
2.3. Clinical Variables and Sampling Procedures
The recording of the clinical data and the collecting of biological materials were made at three
appointments, at baseline before subgingival instrumentation (t0) and three (t3) and six months (t6)
after subgingival instrumentation. Patients were examined for PD, CAL and BOP and the full-mouth
plaque score (FMPS). PD, CAL and BOP were determined in a six-point measurement per tooth
(mesiobuccal, distobuccal, buccal, mesiooral, distooral and oral) using a manual periodontal probe
(PCVNCKIT6, Hu-Friedy Manufacturing Co., Chicago, IL, USA).
For the collection of the gingival crevicular fluid (GCF), sterile paper strips (Periopaper,
Oraflow Inc., Smithtown, NY, USA) were left at the pocket entrance of the deepest pocket at baseline
in each quadrant for 30 seconds. The periopaper strips were transferred into Eppendorf safe-lock
tubes, containing proteinase inhibitor (Sigma-Aldrich, St. Louis, MO, USA), and stored for a few
days at −20 ◦C and thereafter at −80 ◦C until assayed. Samples of the subgingival biofilm were
collected at the same sites by inserting a paper point (ISO 60, Roecko, Langenau, Germany) for
30 s. All collected GCF and biofilm samples were analyzed at the Laboratory of Oral Microbiology,
Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland.
2.4. Biomarkers and Microbiological Analysis
Prior to the analysis, GCF samples were eluted at 4 ◦C overnight in 750 µL phosphate-buffered
saline. From the eluates, the levels of interleukin (IL)-1β and matrix-metalloprotease (MMP)-8
were determined by using commercially available enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems Europe Ltd., Abingdon, UK). These kits had detection levels of 1 pg/site for IL-1β and
100 pg/site for MMP-8 and were used according to the instructions of the manufacturer.
From all subgingival biofilm samples, DNA was extracted by using Chelex method [25].
Samples taken at baseline were screened for presence of A. actinomycetemcomitans by using real-time
PCR [26]. When being negatively tested for A. actinomycetemcomitans, those samples and all
samples collected at the follow-up time points were processed as described recently [27]. In short,
a multiplex-real-time qPCR was performed that quantified A. actinomycetemcomitans, P. gingivalis,
T. forsythia and T. denticola by using specific primers and probes. The results of the bacterial counts are
given in log10. The sensitivity for the method is 102 for each bacterial species.
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2.5. Data Analysis
The clinical and laboratory data were statistically analyzed with the Statistical Package for Social
Sciences (SPSS version 24.0 SPSS Inc., Chicago, IL, USA). The primary outcome variable was the
change of PD in periodontal pockets with initial PD ≥ 6 mm after six months. Based on the data
of Haffajee et al. [28], a mean difference of 0.26 mm in observed PD in initial sites with PD ≥ 6 mm
with a standard deviation of 0.32 mm between the two groups dates would require ≥ 24 patients per
group in order to detect a significant difference (p ≤ 0.05) with a test power of 80%.
Secondary outcome variables were changes of mean PD, BOP, CAL and the number of sites with
PD ≥ 6 mm, levels of IL-1β and MMP-8 as well as the CFU of the studied periodontopathogenic bacteria
after three and six months. All analyses assumed the patient as the statistical unit. Nonparametric
tests (Friedman/Wilcoxon) were used for intra-group testing, and the Mann–Whitney U test was used
for inter-group testing. The level of significance was α ≤ 0.05.
2.6. Ethics Statements
All procedures performed in studies involving human participants were in accordance with the
ethical standards of the institutional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
2.7. Informed Consent
Informed consent was obtained from all individual participants included in the study.
3. Results
3.1. Study Population and Clinical Variables
This randomized controlled trial took place during July 2016 and June 2018. From the primary,
cohort 28 patients were excluded for not matching the criteria or for refusing to participate. A total
of 29 patients per group entered the study. The demographic data are shown in Table 1, and the
study flow is given in the flowchart adapted to Moher et al. [29] in Figure 1. The patients had on
average 25.7 ± 3.1 teeth and 15.1 ± 5.7 teeth with PD ≥ 6 mm in the AMX/MET and 25.7 ± 3.1 teeth
and 14.7 ± 7.8 teeth with PD ≥ 6 mm in the MET group (p = 0.561; p = 0.488). None of the individuals
reported any adverse effects from the prescribed antibiotics or the subgingival instrumentation.
The clinical results are given in Table 2. In both groups, the subgingival instrumentation with
adjunctive antibiotic therapy resulted in significant improvements of PD, CAL and BOP after three and
six months (all p < 0.001). The mean PD of the sites with initial PD ≥ 6 mm as well as the number of
sites with PD ≥ 6 mm also improved significantly (p < 0.001) in both groups after three and six months;
however, the reduction of PD was higher in the AMX/MET than in the MET group at three months
(0.42 mm in median; p = 0.011) and at six months (0.32 mm in median; p = 0.032).
Table 1. Demographic data in the MET (subgingival instrumentation+metronidazole) and
the AMX/MET groups (subgingival instrumentation+metronidazole/amoxicillin) at baseline
(before subgingival instrumentation).
Variable MET Group (n = 29) AMX/MET Group (n = 29) p
Age (years; mean ± SD) 55.14 ± 11.48 52.17 ± 10.16 0.171
Male/female, n 20/9 18/11 0.581
Smoker, n 16 15 0.792
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Figure 1. Flowchart (adapted to Moher et al. [29]) of the study non-surgical periodontal therapy
with adjunctive amoxicillin/metronidazole or metronidazole in the absence of Aggregatibacter
actinomycetemcomitans—a randomized clinical trial.
3.2. Tested Bacteria Associated with Periodontal Disease
The absence (no detection) of A. actinomycetemcomitans at baseline was a require ent for entering
the clini al trial. Rechecking again after three and six onths also did not detect that bacterial sp cies.
The counts f P. gingivalis and T. forsythia were significantly reduced in both groups after three and six
m nths (each p < 0.01). At three onths, T. dent ola decreased only in e AMX/MET group (p < 0.01),
at six months in both groups (each p < 0.05). At three months, the cou ts of T. forsythia were less in
the AMX/MET group than i the MET group (p = 0.042), T. denticola by trend (p = 0.075). All other
differences between the groups were not statistically significant. The results are given in Table 3.
3.3. Biomarkers
No statistically significant difference was found at intra- and inter-group testing. However,
by trend, the levels of IL-1β and MMP-8 decreased to a higher degree in the AMX/MET than in the
MET group after three months (p = 0.096 and 0.084, Table 4).
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Table 2. Clinical variables (median, 25 percentile, 75 percentile) at baseline, after three and six months in the MET (subgingival instrumentation+metronidazole;
n = 29) and the AMX/MET groups (subgingival instrumentation+metronidazole/amoxicillin; n = 29).
Variable Baseline 3 Months P (Baseline–3Months) 6 Months
P (Baseline–6
Months)
Difference
Baseline–3 Months
Difference
Baseline–6 Months
Mean CAL (mm)
MET 4.58 (4.21/5.01) 3.77 (3.59/4.03) <0.001 * 3.77 (3.55/4.15) <0.001 * 0.72 (0.41/1.20) 0.61 (0.45/1.11)
AMX/MET 4.67 (4.14/4.0) 3.73 (3.61/4.08) <0.001 * 3.77 (3.64/4.21) <0.001 * 0.84 (0.49/1.15) 0.65 (0.45/1.19)
P 0.988 0.988 0.630 0.852 0.822
BOP (%)
MET 75.9 (37.64/100) 12.8 (10.6/15.9) <0.001 * 13.1 (0.9/8.99) <0.001 * 64.7 (19.6/87.4) 59.9 (19.9/86.7)
AMX/MET 81.0 (44.49/100) 13.7 (11.9/15.9) <0.001 * 12.6 (11.7/19.2) <0.001 * 56.1 (25.7/86.4) 53.3 (30.3/87.6)
P 0.955 0.262 0.785 0.780 0.697
Mean PD (mm)
MET 4.44 (4.16/4.83) 3.64 (3.48/3.80) <0.001 * 3.67 (3.50/3.79) <0.001 * 0.69 (0.47/1.22) 0.66 (0.46/1.21)
AMX/MET 4.55 (4.15/4.95) 3.62 (3.47/3.91) <0.001 * 3.69 (3.66/3.9) <0.001 * 0.92 (0.5/1.1) 0.83 (0.47/1.18)
P 0.602 0.932 0.355 0.474 0.816
Number of sites with PD ≥ 6 mm
MET 27 (16.5/44) 5 (2/8.5) 0.001 * 4 (2/9) <0.001 * 20 (14/39) 21 (13.5/37)
AMX/MET 33 (17/43) 6 (2/8.5) <0.001 * 5 (3.5/9.5) <0.001 * 26 (15/37) 28 (14.5/38)
P 0.641 0.956 0.894 0.549 0.570
Mean PD of sites with initial PD ≥ 6 mm (mm)
MET 7.04 (6.47/7.44) 4.95 (4.65/5.38) <0.001 4.86 (4.45/5.31) <0.001 * 2.09 (1.44/2.66) 2.19 (1.73/2.76)
AMX/MET 7.19 (6.67/7.61) 4.68 (4.30/5.01) <0.001 4.68 (4.30/5.02) <0.001 * 2.51 (2.00/2.76) 2.51 (2.12/2.88)
P 0.234 0.052 0.197 0.011 # 0.032 #
* statistically significant difference—Wilcoxon signed rank test within the group vs. baseline; # statistically significant difference—Mann–Whitney U test between the groups.
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Table 3. Bacterial counts (log10, median, 25 percentile, 75 percentile)/sample of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Treponema denticola
and Tannerella forsythia at baseline, after three and six months in the MET (subgingival instrumentation+metronidazole) and the AMX/MET groups
(subgingival instrumentation+metronidazole/amoxicillin).
Baseline 3 Months P (Baseline–3 Months) 6 Months P (Baseline–6 Months)
A. actinomycetemcomitans
MET 0 (0/0) 0 (0/0) n.a. 0 (0/0) n.a.
AMX/MET 0 (0/0) 0 (0/0) n.a. 0 (0/0) n.a.
P n.a. n.a. n.a.
P. gingivalis
MET 4.36 (0/5.55) 0(0/3.37) 0.001 * 0 (0/3.24) 0.001 *
AMX/MET 4(0/5.83) 0 (0/0) 0.001 * 0 (0/2.12) 0.003 *
P 0.647 0.288 0.353
T. forsythia
MET 5.84 (5.5/6.4) 4.23 (3.77/5.4) 0.001 * 4.8 (3.24/5.55) 0.004 *
AMX/MET 5.76 (5.25/6.31) 3.56 (2.60/4.68) <0.001 * 4.53 (3.73/5.17) 0.002 *
P 0.652 0.042 # 0.613
T. denticola
MET 3.15 (0/4.32) 2.52 (0/3.56) 0.140 2.28 (0/3.44) 0.028 *
AMX/MET 3.54 (0/4.8) 0 (0/3.25) 0.005 * 2.78 (0/3.5) 0.027 *
P 0.358 0.075 0.416
* statistically significant difference—Wilcoxon signed rank test within the group vs. baseline; # statistically significant difference—Mann–Whitney U test between the groups.
Table 4. Biomarker levels (pg/sample; median (25 percentile/75 percentile) at baseline, after three and six months in the MET (subgingival instrumentation+metronidazole)
and the AMX/MET groups (subgingival instrumentation+metronidazole/amoxicillin).
Baseline 3 Months P (Baseline–3 Months) 6 Months P (Baseline–6 Months)
MMP-8
MET 1794.8 (805.7/2977.0) 758.52 (359.7/2224.0) 0.424 2358.08 (815.6/6478.1) 0.471
AMX/MET 1776.81 (702.5/4123.2) 722.64 (233.9/8593.0) 0.096 2132.96 (145.2/7099.4) 0.495
P 0.886 0.528 0.461
IL-1β
MET 18.24 (7.39/41.11) 8.51 (2.35/18.16) 0.949 17.62 (6.19/44.98) 0.471
AMX/MET 18.17 (11.83/35.71) 10 (2.92/29) 0.084 9.49 (3.12/41.89) 0.909
P 0.702 0.414 0.268
Wilcoxon signed rank test: no significant longitudinal changes compared to baseline; Mann–Whitney U test: no significant differences between the groups.
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4. Discussion
Subgingival instrumentation significantly reduces probing depth, clinical attachment level and
bleeding on probing in periodontitis patients [6–8]. The adjunctive therapy with systemic antibiotics in
patients with severe affected sites by periodontitis improves these clinical results further and reduces
the need for surgical periodontal therapy [11,30].
In the present study, two antibiotic regimens, a combination of two antibiotics and a single
antibiotic administration were compared. In both groups, metronidazole was applied; in one group,
amoxicillin was also applied. When using only a single antibiotic, side effects by the second might be
avoided. A major side effect of amoxicillin is an allergic reaction; about 8% of the US population has a
history of penicillin allergy [31]. The systematic review by Teughels et al. [11] suggests more adverse
effects by AMX/MET than by other antibiotics in periodontal therapy.
Initially, the combination of amoxicillin and metronidazole was introduced to treat “A. actinomycetemcomitans-
associated” periodontitis [32]. In vitro, it was shown that amoxicillin augments the uptake of metronidazole
into the bacterial cell and induces in such a way a synergistic effect in killing the bacteria by the antibiotics [33].
Meanwhile, the combination of amoxicillin and metronidazole is the most used antibiotic regimen in periodontal
therapy; its adjunctive benefit over subgingival instrumentation alone was justified in several systematic
reviews [11,23,34].
Amoxicillin and metronidazole are administered in different dosages (250–500 mg amoxicillin and
200–500 mg metronidazole per application), in general applied three times per day, for different periods
(from 3 days up to 14 days) [11,23,35]. In our study, the used dosage (500 mg amoxicillin/400 mg
metronidazole) was given to the patients three times per day for seven days following the schedule of
Harks 2015 [36].
In the present study, the PD reduction of sites with initial PD ≥ 6 mm (primary outcome)
was significantly better in the AMX/MET than in the MET group. This was not accompanied by a
significant higher reduction in the number of sites with PD ≥ 6 mm. When considering only the need
for periodontal surgery (PD ≥ 6 mm requires further periodontal therapy), Matuliene et al.’s [37]
administration of solely metronidazole might be sufficient. In the AMX/MET group, the reduction was
a median of 2.5 mm after three months, which remained stable after six months. The reduction of PD
and the attachment gain are in coincidence to improvements reported in the literature; higher than
those reported by Boia et al. [38] and Morales et al. [39] but lower than in the study of Duarte et al. [40]
or Mombelli et al. [41]. Our study reports improvements of sites with initial ≥6 mm as described by
Duarte et al. [40] to evaluate the status of closed pocket and incomplete periodontal therapy related to
the necessity of additional surgical periodontal therapy [37,42].
Clinical studies comparing metronidazole alone with amoxicillin and metronidazole in periodontal
therapy are rare. One study with 66 participants in four study groups (inclusive solely amoxicillin and
placebo groups) reported higher improvements of PD, CAL and BOP after six months when amoxicillin
+ metronidazole was adjunctively administered than metronidazole alone [43]. Another study with a
follow-up of one year and also including a placebo group resulted in clinical superiority of both antibiotic
regimens but just had a trend (no statistical significance) to the better outcome of the combined antibiotic
therapy versus metronidazole alone [44]. To the best of the authors’ knowledge, after a thorough
search of the literature, no paper was found that addressed the comparison between the adjunctive
therapy with amoxicillin/metronidazole or metronidazole in periodontitis patients tested negative for
A. actinomycetemcomitans in the subgingival biofilm before nonsurgical periodontal treatment.
The better results for amoxicillin and metronidazole than for metronidazole alone in absence
of A. actinomycetemcomitans raise once more the question of the significance of microbiological
diagnostics in the treatment planning of periodontal therapy. It might be the goal of an antibiotic
therapy to target bacterial species playing a crucial role in the pathogenesis of the disease and
to preserve the commensals [45]. For that the identification of potential pathogens might be of
interest. Clinical results, also after adjunctive antibiotic therapy, often did not see any association
with the detection of selected microorganisms, e.g., A. actinomycetemcomitans [41,46]. Otherwise,
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our retrospective analysis suggested that patients with P. gingivalis, T. forsythia and T. denticola benefit
from adjunctive amoxicillin/metronidazole. On the other hand, it should be also seriously questioned
if adjunctive antibiotics are really needed in periodontal therapy [24]. An analysis including more than
300 patients revealed that patients younger than 55 years and having more than 35 % of PD ≥ 5 mm
benefit most from adjunctive amoxicillin and metronidazole [13]. Considering the increasing resistance
to antibiotics, it is of interest to identify patients who will complete the periodontal therapy successfully
only with adjunctive antibiotics.
The few available in vitro data on antibiotic resistance suggest a high susceptibility rate of
T. forsythia to metronidazole [47,48]. However, in the present study, AMXTMET showed an even
stronger depletion of T. forsythia and T. denticola. A synergistic effect of amoxicillin with metronidazole
has to be assumed. A direct antibacterial synergism was not found against P. gingivalis, but neither
T. forsythia nor T. denticola were tested [49]. Combinations of antibiotics augment their intracellular
activities, as shown for moxifloxacin when combined with metronidazole in epithelial cells infected
with P. gingivalis [50].
The combination of amoxicillin with metronidazole was also found to be more active than
metronidazole alone in diverse biofilm models. The combination of the antibiotics decreased the
metabolic activity in a three-species biofilm model of Streptococcus sanguinis, Fusobacterium nucleatum
and P. gingivalis, and, in a ten-species biofilm model, the combined administration of antibiotics reduced
the bacterial counts and strengthened P. gingivalis but not T. forsythia or T. denticola [51].
In the present study, periodontal inflammation seemed to be more reduced in the AMX/MET
than in the MET group. This can be concluded from the lower results of BOP by trend (no statistical
significance) after six months as well as from lower inflammatory biomarkers in the GCF, IL-1β and
MMP-8, by trend (no statistical significance) after three months. It might be an indirect effect via
changed microbiota or by a direct effect of antibiotics on the immune response; e.g., amoxicillin is able
to decrease the release of the proinflammatory tumor-necrosis factor (TNF)-α from human monocytes
exposed to lipopolysaccharides [52]. Metronidazole reduced the release of inflammatory cytokines
from periodontal ligament fibroblasts stimulated with the LPS of P. gingivalis [53]. Wang et al. [54]
found a decrease of IL-6 in the serum of rats after the adjunctive administration of amoxicillin and
metronidazole during nonsurgical periodontal therapy. Al-Khureif et al. [55] reported increased levels
of IL-10 and reduced levels of lL-17 in the gingival crevicular fluid of periodontitis patients after
subgingival instrumentation and adjunctive antibiotic therapy with amoxicillin and metronidazole.
These studies did not include groups with just one of these combined used antibiotics. Thus, it remains
unclear if the nonbacterial effect is due to amoxillin or metronidazole.
There are some limitations of the present study. A third group without adjunctive antibiotic treatment
as a negative control was not included. Moreover, the patients were not blinded to the antibiotics.
In summary, within the limits of the present study, it can be concluded that metronidazole is
weaker than amoxicillin/metronidazole as an adjunct to subgingival instrumentation in patients with
severe periodontitis and that tested A. actinomycetemcomitans negative in the subgingival biofilm.
The adjunctive systemic use of amoxicillin/metronidazole results in better clinical and microbiological
outcomes and is recommended in all patients who need adjunctive antibiotics in periodontal therapy.
5. Conclusions
When A. actinomycetemcomitans is not detected in the subgingival biofilm, the adjunctive
systemic use of amoxicillin/metronidazole results in better clinical and microbiological outcomes than
metronidazole alone of non-surgical periodontal therapy when, after a careful weighted decision
considering the potential side effects, the application of systemic antibiotics is scheduled.
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